HIGH

Fagron Compounding Services Norepinephrine Bitartrate Injection Recall Affects 5,140 Bags (2026)

Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.

Quick Facts at a Glance

Recall Date
March 20, 2026
Hazard Level
HIGH
Brand
Fagron Compounding Services
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, ELDERLY

Hazard Information

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Fagron Compounding Services or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Norepinephrine Bitartrate injections are used as vasopressors in critical care to raise blood pressure in hypotensive patients. They are typically prepared in hospital pharmacies or compounding centers.

Why This Is Dangerous

A blue Break-Off-Part could detach from the administration port, raising sterility concerns and potential contamination risk.

Industry Context

This recall is not part of a broader industry pattern beyond sterility assurance issues in compounded IV solutions.

Real-World Impact

Immediate discontinuation is required for affected bags. Hospitals and patients may experience delays in critical vasopressor therapy while replacements are sourced.

Practical Guidance

How to identify if yours is affected

  1. Cross-check lot numbers against the list: C274-000050004, C274-000050295, C274-000050773, C274-000051219, C274-000051318, C274-000051602.
  2. Verify expiration dates: 4/24/2026, 5/8/2026, 6/4/2026, 6/21/2026, 6/27/2026, 7/12/2026.
  3. Confirm NDC 71266-5027-02 and product description.

Where to find product info

Recall details are on FDA enforcement page and packaging labels.

What timeline to expect

Refunds/replacements typically managed through hospital purchasing channels; no public timeline specified.

If the manufacturer is unresponsive

  • Engage hospital risk management or compliance.
  • File a formal inquiry with the manufacturer and FDA if no response within a reasonable period.

How to prevent similar issues

  • Implement strict lot-based inventory control.
  • Institute supplier sterility confirmation before use.
  • Audit compounded IV solutions for break-off components.

Documentation advice

Document lot numbers, expiration dates, and correspondences with the manufacturer and FDA.

Product Details

Product: Norepinephrine Bitartrate, 32 mg per 250 mL 0.9% Sodium Chloride Injection USP. Company: Fagron Compounding Services. Address: 8710 34th St. N. Wichita, KS 67226. NDC: 71266-5027-02. Lot numbers and expirations include: C274-000050004 Exp. 4/24/2026; C274-000050295 Exp. 5/8/2026; C274-000050773 Exp. 6/4/2026; C274-000051219 Exp. 6/21/2026; C274-000051318 Exp. 6/27/2026; C274-000051602 Exp. 7/12/2026. Quantity: 5140 bags. Distribution: Nationwide in the USA. Recall date: 2026-03-20.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 5,140 bags recalled
  • NDC 71266-5027-02
  • Lot numbers with expirations listed (4/24/2026 to 7/12/2026)
  • Nationwide distribution in the U.S.
  • Hazard: lack of sterility assurance; blue Break-Off-Part could detach

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTELDERLYPETS
Injury Types
ELECTRICALPOISONINGLACERATIONOTHER

Product Details

Model Numbers
Lot: C274-000050004 Exp.: 4/24/2026
Lot: C274-000050295 Exp.: 5/8/2026
Lot: C274-000050773 Exp.: 6/4/2026
Lot: C274-000051219 Exp.: 6/21/2026
Lot: C274-000051318 Exp.: 6/27/2026
+1 more
Affected States
ALL
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more